Open Access
Subscription Access
Journey from Coronavirus Pandemic to Vaccines
No Abstract.
Keywords
No Keywords
User
Font Size
Information
- Callaway E, Ledford H, Viglione G, Watson T, Witze A. COVID and 2020: An extraordinary year for science. Nature. 2020; 588: 550-552.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384:403-416.
- Selectscience.net. 2021. AZD1222 vaccine met efficacy endpoint in preventing COVID-19. [online] Available at: https://www.selectscience.net/industrynews/ astrazeneca-covid-19-vaccine-azd1222-metprimaryefficacy-endpoint/?artID=53242 [Accessed 24 January 2021].
- Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Gischolar_main, A., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., Berghmans, P., Kimmel, M., Van Damme, P., de Hoon, J., Smith, W., Stephenson, K., De Rosa, S., Cohen, K., McElrath, M., Cormier, E., Scheper, G., Barouch, D., Hendriks, J., Struyf, F., Douoguih, M., Van Hoof, J. and Schuitemaker, H., 2021. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med.
- Pfizer.com. 2021. Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints | Pfizer. [online] Available at: https://www.pfizer.com/news/ press-release/press-release-detail/pfizer-andbiontechconclude-phase-3-study-covid-19-vaccine [Accessed 31 January 2021].
- Moderna, Inc. 2021. Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc.. [online] Available at: https://in vestors.modernatx.com/news-releases/news-release -details/modernas-covid-19-vaccine-candidatemeetsits-primary-efficacy/ [Accessed 1 February 2021].
- En.wikipedia.org. 2021. Sputnik V COVID-19 vaccine. [online] Available at: https://en.wikipedia.org/wiki/Sputnik_V_COVID-19_vaccine [Accessed 11 February 2021].
- Mallapaty, S., 2021. China COVID vaccine reports mixed results — what does that mean for the pandemic?. [online] https://www.nature.com. Avail able at: https://www.nature.com/articles/d41586-02100094-z [Accessed 2 February 2021].
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine
- (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397: 99-111.
- Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis 2021 pp. 1-10.
- Poland GA, Ovsyannikova IG, Kennedy RB. SARSCoV2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020; 396: 1595-1606.
Abstract Views: 494
PDF Views: 270